CJC-1295 half life and GH/IGF-1 duration
The compound, growth hormone and IGF-1 each have their own timing result. Putting them on the same page makes the differences visible.
The reported time windows
The healthy-adult study by Teichman and colleagues supplies several durations that often get bundled together. CJC-1295 DAC had an estimated half-life of 5.8-8.1 days. Mean growth hormone was elevated for 6 days or more. IGF-1 was elevated for 9-11 days after a single dose, and remained above baseline up to 28 days after multiple doses.
Half-life describes the time for the circulating concentration of the compound to fall by half. The other windows describe hormone responses. The 28-day result also comes from a different dosing condition. My frustration with a single headline duration is that it silently erases all three distinctions.
Albumin-bound CJC-1295
The albumin-conjugation experiments give the long duration a chemical explanation. The stabilised peptide binds circulating albumin through its DAC handle. In rats, the compound was detectable beyond 72 hours; in vitro work examined its resistance to enzymatic breakdown.
The human half-life estimate comes from the subsequent volunteer study. I like this sequence because the explanation and the measurement line up without needing a claim about recovery or anti-aging. The DAC comparison follows what changes when the albumin-binding part is absent.
Basal GH and pulsatility
In Ionescu and Frohman’s study, basal growth hormone was approximately 7.5-fold higher one week after CJC-1295. Mean growth hormone was about 46% higher and IGF-1 about 45% higher. The men were healthy and aged 20-40; the single study doses were 60 or 90 micrograms/kg.
Frequency and magnitude of growth-hormone pulses were unaltered. The increased basal level therefore deserves its own line in the account. The familiar pulse pattern continued on top of that raised background.
I resist calling this pattern inherently better. The experiment describes secretion; deciding what pattern produces worthwhile health outcomes requires a different kind of result.
Repeated exposure over longer periods
The up-to-28-day IGF-1 finding after multiple doses documents a persistent response in the early human experiment. It leaves the consequences of months or years of exposure unresolved. Large efficacy and long-term safety trials in healthy adults are absent.
That gap matters particularly because higher circulating IGF-1 has epidemiological links to certain cancers. Those population associations supply a reason for caution; they have not established that CJC-1295 causes cancer. That persistence deepens my unease about the missing follow-up.